The trial is for an immunotherapeutic treatment for Multiple Sclerosis, involves patients in six countries across Europe and starts in October.
In addition, Venn's Interactive Response Technology (IRT) department, which selects patients for trials, has picked up a project in China from a top ten pharma major after being approved by the group as a service provider.
Venn hailed this deal, saying vendor qualification is a significant milestone for the IRT division and represents an exciting opportunity to grow a global account.
Tony Richardson, chief executive, added Venn was now benefiting from a good balance of repeat business, client referrals and new business wins.
“I am particularly pleased with our success in IRT. Coming through the vendor qualification and audit process with 'big-pharma' represents a significant step for our organisation and high quality execution of this initial project should result in a rich vein of new business."
A specialist contract research organisation (CRO), Venn Life provides an outsourcing service for drug development, clinical trial management and resourcing solutions.